Bright Minds Biosciences (DRUG) Asset Writedowns and Impairment (2022 - 2026)
Bright Minds Biosciences (DRUG) posted Asset Writedowns and Impairment of $4011.4 for Q1 2026, down 14.96% on a QoQ basis from $4717.0 in Q4 2025, and down 57.62% year-over-year from $9464.1 in Q1 2025.
Bright Minds Biosciences (DRUG) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Bright Minds Biosciences' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $4011.4 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn |
| 10 | Bright Minds Biosciences | 684.04 Mn | 684.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,011.36 |
| Mar 31, 2026 | 4,011.36 |
| Dec 31, 2025 | 4,716.99 |
| Dec 31, 2025 | 4,716.99 |
| Jun 30, 2025 | 6,147.55 |
| Jun 30, 2025 | 6,147.55 |
| Mar 31, 2025 | 9,464.13 |
| Mar 31, 2025 | 9,464.13 |
| Dec 31, 2024 | 4,622.24 |
| Dec 31, 2024 | 4,622.24 |
| Jun 30, 2024 | -176.94 |
| Jun 30, 2024 | -176.94 |
| Mar 31, 2024 | 1,577.73 |
| Mar 31, 2024 | 1,577.73 |
| Dec 31, 2023 | 2,182.31 |
| Dec 31, 2023 | 2,182.31 |
| Jun 30, 2023 | 3,406.61 |
| Jun 30, 2023 | 3,406.61 |
| Mar 31, 2023 | 3,944.80 |
| Mar 31, 2023 | 3,944.80 |